UBS raises Certara stock price target on software demand strength
UBS raised its price target for Certara (CERT) to $13.00 from $10.00, citing strong software demand. Software bookings rose 15% YoY, and revenue grew 11% in the quarter. Management raised revenue guidance. The stock is up 94.6% over six months. Q3 2026 revenue was $94.9M, beating estimates, with software sales up 11%.
How this was made
The 30-second read
Why it matters
The upgrade could attract new buying interest, especially from investors focused on high‑growth biotech software firms.
Market read
Analyst upgrade may drive short‑term buying pressure in Certara and influence sentiment in the broader biotech software niche.
What to watch
Potential headwinds from regulatory changes or competition in drug‑development software could temper growth.
Background
UBS analysts cite a 15% YoY rise in software bookings and an 11% software revenue increase in Q3 2026, prompting a price target lift.
Ticker impact
UBS raised its price target on Certara to $13 from $10 and reported stronger software revenue and guidance, providing fresh analyst coverage.
likely upward pressure as the market prices in the higher target and improved software outlook
The price target increase and guidance raise suggest better near‑term earnings, prompting traders to consider buying on potential upside.
Market effects
Positive signal for the biotech software sector as Certara's software bookings accelerate.
U.S. biotech stocks may see modest gains from the upgrade.
Limited to investors tracking U.S. biotech and software service providers.
Counterpoint
The upgrade may be premature if services bookings remain weak and the software re‑acceleration stalls.
Key entities
- companyCertara Inc.
Provider of drug‑development software and services.
- analyst_firmUBS
Investment bank that raised Certara's price target.





